<DOC>
	<DOCNO>NCT01504347</DOCNO>
	<brief_summary>Section 1 : The purpose study obtain safety immunogenicity data different dose level multivalent recombinant OspA Lyme Borreliosis ( mv rOspA LB ) Vaccine without adjuvant seronegative healthy adult age 18 70 year . The outcome shall provide basis dose/formulation selection Section 2 study . Section 2 : An additional purpose study evaluate safety immunogenicity optimal dose ( ) /formulation mv rOspA LB Vaccine large population seronegative seropositive healthy subject age 18 70 year .</brief_summary>
	<brief_title>Phase 1/2 Lyme Vaccine Study</brief_title>
	<detailed_description />
	<mesh_term>Borrelia Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Main Subject 18 70 year old time screen Subject understanding study , agree provision , give write informed consent prior study entry Subject generally healthy , determine investigator 's clinical judgment collection medical history performance physical examination If female childbearing potential , present negative urine pregnancy test , agree employ adequate birth control measure duration study Additional inclusion criterion seropositive subject Section 2 : Subject seropositive Borrelia burgdorferi sensu lato ( s.l . ) antibody study entry Main Subject physiciandiagnosed chronic illness relate Lyme borreliosis ( LB ) active LB Subject treat LB antibiotic within 3 month study entry Subject tick bite within 3 week prior screen first vaccination Subject history active infection Babesia microti ( babesiosis ) Anaplasma phagocytophilum ( ehrlichiosis ) Subject currently history significant cardiovascular , respiratory ( include asthma ) , metabolic , neurological , hepatic , rheumatic , autoimmune , hematological , gastrointestinal renal disorder Subject clinically significant abnormal laboratory value screen Subject currently history immunodeficiency Subject test positive human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) Subject disease currently undergoing form treatment undergoing form treatment within 30 day prior study entry could expect influence immune response . Subject history anaphylaxis severe allergic reaction Subject receive live vaccine within 4 week inactivate vaccine within 2 week prior vaccination study Subject pregnant lactating time study enrollment Additional exclusion criterion subject Section 1 seronegative subject Section 2 : Subject seropositive Borrelia burgdorferi sensu lato ( s.l . ) antibody study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>